Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066429
Filing Date
2025-05-08
Accepted
2025-05-08 08:10:25
Documents
102
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mnkd-20250331.htm   iXBRL 10-Q 2823197
2 EX-10.1 mnkd-ex10_1.htm EX-10.1 13094
3 EX-10.2 mnkd-ex10_2.htm EX-10.2 17065
4 EX-10.3 mnkd-ex10_3.htm EX-10.3 18567
5 EX-31.1 mnkd-ex31_1.htm EX-31.1 15362
6 EX-31.2 mnkd-ex31_2.htm EX-31.2 15361
7 EX-32.1 mnkd-ex32_1.htm EX-32.1 10949
8 EX-32.2 mnkd-ex32_2.htm EX-32.2 10961
  Complete submission text file 0000950170-25-066429.txt   14289716

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mnkd-20250331.xsd EX-101.SCH 2406662
105 EXTRACTED XBRL INSTANCE DOCUMENT mnkd-20250331_htm.xml XML 2584330
Mailing Address 1 CASPER STREET DANBURY CT 06810
Business Address 1 CASPER STREET DANBURY CT 06810 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50865 | Film No.: 25924002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)